"Whether it's this year or next year, the odds of another economic downturn are high — and growing," Warren says.Politicsread more
The agreement between the White House and congressional Democrats would raise the debt ceiling for two years and permanently end the sequester.Politicsread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
Microsoft and OpenAI announced a new partnership to build artificial general intelligence to tackle more complex tasks than current AI.Technologyread more
A group of gold miners stocks "BAANG" are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
The Iranian Intelligence Ministry held a briefing on Monday where they announced the alleged spies were Iranian citizens but trained by the CIA.World Newsread more
Two traders say Boeing's on the path to recovery.Trading Nationread more
Documents leaked to The Washington Post revealed that Huawei secretly worked with the North Korean government on its wireless network.Technologyread more
Equifax will pay at least $575 million, and potentially as much as $700 million, to settle allegations over its massive over 2017 data breach, U.S. regulators said in a...Technologyread more
CNBC's Mike Santoli breaks down the aggressive buying of "sure things" and shunning of cyclical and policy risk.Trading Nationread more
Facebook has seen an increase in the median number of comments, likes and ads clicked by users on the service from January to July, according to Audience Insights, a Facebook...Technologyread more
SAN ANTONIO, July 07, 2016 (GLOBE NEWSWIRE) -- bioAffinity Technologies today announced that William Bauta, Ph.D., will join the company in September 2016 as Senior Vice President for Research and Development, Therapeutics. Dr. Bauta will direct the development and commercialization of targeted drugs for the treatment of multiple cancers at bioAffinity’s wholly owned subsidiary, OncoSelect Therapeutics, LLC.
“Dr. Bauta’s 25 years of experience in the discovery, development and commercialization of pharmaceuticals for oncology and a wide array of life-threatening diseases will shorten the timeframe to adapt our proprietary porphyrin-based technology to the targeted cancer therapeutics market,” said bioAffinity President and CEO Maria Zannes. “His expertise in the field of medicinal chemistry complements and builds upon the extraordinary caliber of our scientific team under the direction of Dr. Vivienne Rebel.”
Dr. Bauta is currently the manager for medicinal and process chemistry at Southwest Research Institute where he helped develop its pharmaceuticals services and bioengineering business. Previously, he was Associate Director of science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible for the discovery, development and FDA approval of multiple therapeutics. He holds several patents and has published in more than a dozen scientific journals, including the journal Science. Dr. Bauta received his Ph.D. from the University of Chicago where he received fellowships from the National Science Foundation and the American Chemical Society. His post-doctoral studies were at the University of Texas at Austin under a National Institutes of Health fellowship.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence detectable by an imaging system. OncoSelect will take advantage of CyPath®’s unique characteristics to deliver targeted porphyrin therapeutics that will be available to partners through a variety of licensing agreements.
About bioAffinity Technologies
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor, and treat many cancers. CyPath® Lung, bioAffinity’s initial product, is designed to be the first successful non-invasive, early-stage lung cancer diagnostic on the market.
Contact: Maria Zannes, 505.400.9747
Source: bioAffinityTechnologies, Inc.